Abiraterone acetate and enzalutamide are oral androgen signaling inhibitor therapies used in the treatment of patients with advanced prostate cancer. However, because elderly patients with prostate cancer who also have cardiovascular disease are often excluded from clinical trials, little has been known about the effect of these therapies on the clinical outcomes of these patients. In this interview with i3 Health, Grace Lu-Yao, PhD, MPH, discusses the increased mortality and hospitalization ris...

Abiraterone acetate and enzalutamide, two oral androgen signaling inhibitor therapies, have been found to increase mortality in elderly patients with advanced prostate cancer and pre-existing cardiovascular disease (CVD). Many of the clinical trials which led to the approval of abiraterone acetate and enzalutamide for the treatment of advanced prostate cancer excluded elderly patients, defined as those age 65 and older, with cardiovascular comorbidities, such as congestive heart failure, atrial ...

The phase 2 California Cancer Consortium trial has reported its final results: a combined regimen of gemcitabine (Gemzar®, Eli Lilly) plus eribulin (Halaven®, Eisai Inc.) shows efficacy in patients with metastatic urothelial carcinoma who are ineligible for cisplatin-based treatment. Many patients with urothelial carcinoma—the most common type of bladder cancer—that has metastasized are ineligible for chemotherapy treatments containing cisplatin. As such, alternatives are needed for th...

A new technique that utilizes liquid biopsies and conditional reprogramming has the potential to offer personalized treatment strategies for patients with bladder cancer. Accounting for approximately 17,000 deaths in the United States in 2018, bladder cancer is distinctive from many other cancers in that its survival rates have not improved in the past 30 years. Treatment regimens vary due to their dependency on associated risk factors and each patient's personal clinical characteristics. Invest...

​ Five-year overall survival results have now been revealed for nivolumab in advanced melanoma, renal cell carcinoma (RCC), and non-small cell lung cancer (NSCLC). "We report, to our knowledge, the longest combined clinical follow-up for patients with multiple cancer types receiving any anti–PD-L1 drug," the researchers comment in their secondary analysis of data from the phase I CA209-003 trial and expansion cohorts. This trial was the first multidose trial of nivolumab, an immunotherapy drug t...